Genome Publications
https://doi.org/10.61096/978-81-981372-2-7_21

Chapter 21

Digital Health, AI, and Decision-Support in Pharmacology

Priyanka Vemu
Principal Medical Writer, Criterion Edge; 3rd Floor, Plot No 72,
Jubilee hills, Hyderabad-500033, India

Abstract: Digital health innovations and artificial intelligence (AI) are reshaping modern pharmacology, bridging the gap between computational power, clinical decision-making, and patient-centered care. The convergence of machine learning, big data analytics, mobile health applications, biosensors, and telemedicine has provided new avenues for drug discovery, personalized therapy, and real-time pharmacological monitoring. AI-driven platforms now facilitate compound design, virtual screening, and drug repurposing, accelerating the pipeline from bench to bedside. Similarly, clinical decision-support systems (CDSS) integrated within electronic medical records are reducing prescribing errors, optimizing therapeutic regimens, and improving patient safety. Mobile applications and wearable biosensors empower patients through self-management, smart dosing, and continuous monitoring of pharmacokinetic and pharmacodynamic responses. Emerging trends such as digital pharmacovigilance leverage social media and natural language processing to identify adverse drug events at unprecedented speed and scale. AI-enabled clinical trials further improve recruitment, decentralization, and digital phenotyping. However, the digital transformation of pharmacology is not without challenges, particularly around data privacy, algorithmic bias, regulatory oversight, and ethical considerations. Telepharmacy and virtual services extend pharmacist access to remote populations, while futuristic paradigms such as the metaverse, digital twins, and quantum computing promise a more predictive and immersive healthcare ecosystem. This chapter critically examines the applications, limitations, and future scope of digital health and AI in pharmacology, highlighting both transformative potential and cautionary complexities.

Keywords: Digital health, Artificial intelligence, Clinical decision-support, Pharmacovigilance, Telepharmacy.

Citation: Priyanka Vemu, Digital Health, AI and Decission-Support in Pjharmacology. *Modern Therapeutic Pharmacology: Precision Therapeutics Across Organ Systems.* Genome Publications. 2025; Pp223-233. https://doi.org/10.61096/978-81-981372-2-7_21

21.0 INTRODUCTION

The field of pharmacology is undergoing a profound transformation due to the integration of digital health technologies and artificial intelligence (AI). Over the past two decades, pharmacology has shifted from a discipline primarily focused on laboratory experimentation and population-level therapeutic outcomes to one increasingly reliant on computational modeling, big data, and patient-specific decision support. This transition is driven by the exponential growth of biomedical data, the ubiquity of electronic medical records (EMRs), the widespread adoption of mobile devices, and advances in computational algorithms capable of extracting clinically actionable insights from complex datasets [1].

The rise of digital health encompasses a broad ecosystem of technologies, including telemedicine, wearable devices, biosensors, and mobile health applications, all of which facilitate real-time patient monitoring and remote care. Within pharmacology, digital health has a unique role in enabling precision dosing, monitoring pharmacokinetic and pharmacodynamic (PK/PD) profiles, and enhancing medication adherence. Moreover, digital health platforms facilitate rapid feedback loops between patients, clinicians, and researchers, fostering a more adaptive and individualized model of care [2].

Artificial intelligence, particularly machine learning (ML) and deep learning approaches, has emerged as a key enabler of drug discovery, drug repurposing, and therapeutic optimization. These computational systems can analyze chemical libraries, predict drug–target interactions, and design novel molecular scaffolds with far greater efficiency than traditional experimental workflows [3]. In parallel, AI-powered clinical decision-support systems (CDSS) embedded within EMRs are mitigating prescribing errors, suggesting dose adjustments based on real-time patient data, and supporting clinicians in managing polypharmacy.

Importantly, the convergence of AI and digital health aligns with broader healthcare paradigms such as precision medicine and value-based care. Patients are no longer passive recipients of therapy but active participants in managing their health through mobile applications, wearable trackers, and telepharmacy platforms. These technologies, while empowering, also introduce new complexities in terms of data governance, ethical accountability, and regulatory compliance [4].

This chapter provides a comprehensive analysis of the role of digital health and AI in pharmacology, from preclinical discovery to patient-level interventions. It explores the opportunities, limitations, and ethical dilemmas inherent in this digital transition, with a focus on clinical applicability, safety, and sustainability. Ultimately, digital pharmacology represents not merely a technological evolution but a paradigm shift toward more personalized, data-driven, and patient-centered healthcare.

21.1 AI in Drug Discovery and Repurposing

Drug discovery has traditionally been a resource-intensive process, requiring over a decade of development and billions of dollars in investment. Despite these efforts, attrition rates remain high, with many candidate molecules failing during preclinical or clinical evaluation. The integration of AI and ML has revolutionized this landscape by dramatically improving the efficiency of drug design, target identification, and lead optimization.

AI-driven drug discovery leverages large-scale datasets, including chemical libraries, genomic data, proteomic interactions, and clinical trial outcomes, to identify novel compounds with therapeutic potential. Machine learning models can predict drug–target binding affinities, assess off-target effects, and evaluate toxicity risks before laboratory synthesis, reducing early-stage failures [5]. For example,

deep learning frameworks such as AlphaFold have significantly advanced protein structure prediction, accelerating rational drug design [6]. Similarly, generative adversarial networks (GANs) and reinforcement learning have been used to propose entirely new chemical entities optimized for specific pharmacological properties [7].

Drug repurposing, or repositioning, is another area where AI has demonstrated remarkable utility. By mining existing datasets from clinical trials, electronic health records, and biomedical literature, AI systems can identify new indications for approved drugs. This approach shortens development timelines and reduces costs, since safety profiles are already established. Notable successes include the repurposing of thalidomide for multiple myeloma and the discovery of potential applications of metformin in oncology [8]. During the COVID-19 pandemic, AI algorithms were employed to rapidly screen approved drugs for antiviral activity, expediting the identification of candidates such as remdesivir [9].

Comparatively, traditional drug discovery relies heavily on trial-and-error experimentation, high-throughput screening, and serendipitous observations. While effective, this methodology is constrained by time, cost, and limited scalability. In contrast, AI-driven approaches enable hypothesis generation at scale, integrating diverse omics data to generate testable insights. Nonetheless, challenges remain, including algorithm transparency, reproducibility, and the integration of in silico predictions with wet-lab validation [10].

Future perspectives in AI-based drug discovery include the integration of quantum computing for molecular simulations, the use of federated learning to enable collaborative data analysis without compromising privacy, and the development of explainable AI to enhance interpretability for regulatory approval. Together, these innovations hold the potential to reshape the drug discovery pipeline into a more predictive, efficient, and patient-focused process.

21.2 Clinical Decision-Support Systems (CDSS)

Clinical decision-support systems are AI-enabled platforms that assist clinicians in making evidence-based therapeutic choices. Within pharmacology, CDSS applications are particularly valuable in guiding drug selection, optimizing dosing regimens, and reducing adverse drug events. By integrating with EMRs, CDSS platforms can analyze patient-specific data such as demographics, comorbidities, laboratory results, and pharmacogenomic profiles to generate tailored prescribing recommendations [11].

One of the most significant contributions of CDSS is in reducing medication errors, which remain a major cause of morbidity and healthcare costs worldwide. Studies have demonstrated that CDSS implementation reduces inappropriate prescribing, alerts clinicians to potential drug–drug interactions, and improves adherence to clinical guidelines [12]. For instance, dosage adjustment recommendations for patients with renal or hepatic impairment can be automatically flagged, preventing adverse outcomes. Similarly, CDSS can support antibiotic stewardship programs by ensuring appropriate drug choice, dose, and duration [13].

The integration of CDSS with EMRs has created a seamless workflow where decision support is provided in real time at the point of care. Advanced systems utilize natural language processing (NLP) to extract relevant information from unstructured clinical notes, enabling more comprehensive data analysis. Some platforms incorporate predictive analytics, forecasting patient deterioration or risk of drug toxicity before clinical signs appear [14].

Despite these advances, CDSS faces limitations including alert fatigue, where clinicians become desensitized to frequent warnings, potentially overlooking critical alerts. Additionally,

interoperability between different health IT systems remains a challenge, as does the need for system customization to reflect local clinical practices [15].

Future developments aim to enhance the intelligence and usability of CDSS through adaptive learning systems that continuously refine recommendations based on new data and clinician feedback. Integration of pharmacogenomic data and real-world evidence into CDSS could enable truly personalized pharmacotherapy, aligning with the broader vision of precision medicine [16].

21.3 Mobile Health and Apps

Mobile health (mHealth) applications represent a rapidly expanding frontier in digital pharmacology, empowering patients to actively participate in medication management and disease monitoring. These applications leverage the widespread penetration of smartphones to provide accessible, user-friendly platforms for self-care, adherence tracking, and clinician–patient communication.

Smart dosing applications are among the most impactful innovations in this domain. They offer features such as medication reminders, dosing calculators, and drug–drug interaction checkers tailored to individual patient profiles. For example, insulin dosing apps integrate continuous glucose monitoring data to recommend precise adjustments, enhancing glycemic control in diabetes management [17]. Similarly, anticoagulation apps allow for dynamic warfarin dosing adjustments based on patient INR values, reducing the risk of thromboembolic and hemorrhagic complications [18].

Telemedicine platforms also integrate with mobile apps, facilitating virtual consultations and enabling clinicians to remotely monitor patient adherence and therapeutic responses. The COVID-19 pandemic accelerated the adoption of telemedicine, and mobile apps became indispensable in ensuring continuity of care. Chronic conditions such as hypertension, asthma, and epilepsy have benefited from digital self-management tools, improving adherence and patient satisfaction [19].

However, the effectiveness of mHealth apps depends on user engagement, digital literacy, and the reliability of underlying algorithms. Studies have highlighted variability in app quality, with many lacking clinical validation or regulatory approval. Privacy concerns also arise, as sensitive health data collected by apps may be shared with third parties without explicit patient consent [20].

The future of mobile pharmacology apps lies in greater integration with biosensors and EMRs, AI-driven personalization, and regulatory frameworks to ensure clinical safety and efficacy. As these technologies evolve, they are likely to play a central role in empowering patients and supporting clinicians in delivering data-driven, individualized pharmacotherapy.

21.4 Wearables and Biosensors

Wearable technologies and biosensors are redefining pharmacology by enabling real-time monitoring of physiological parameters and drug responses. Devices such as smartwatches, adhesive patches, and implantable sensors provide continuous data on vital signs, activity levels, and biochemical markers, transforming the assessment of pharmacokinetics and pharmacodynamics from intermittent snapshots to dynamic, longitudinal profiles [21].

Continuous glucose monitoring (CGM) devices exemplify the transformative potential of wearables in pharmacology. By providing real-time glucose data, CGMs inform precise insulin dosing and dietary adjustments, improving outcomes for patients with diabetes. Similarly, wearable biosensors capable of monitoring drug levels in interstitial fluid or blood are under development, offering the possibility of personalized, adaptive dosing regimens [22].

In oncology, biosensors are being explored to track circulating tumor DNA and biomarkers, allowing early detection of relapse or resistance to therapy. Cardiovascular pharmacology has also benefited from wearable ECG monitors that detect arrhythmias and guide anticoagulation therapy decisions [23].

Compared with traditional monitoring methods, wearables provide richer datasets, reduce the burden of hospital visits, and enhance patient autonomy. However, limitations include device accuracy, calibration requirements, and the risk of data overload for clinicians. Additionally, interoperability challenges persist, as sensor data must be integrated with EMRs and CDSS for actionable insights [24].

Future developments aim to incorporate multi-analyte sensing, closed-loop drug delivery systems, and AI-driven predictive analytics to transform wearables into proactive therapeutic tools rather than passive monitors. For example, closed-loop insulin delivery, or the "artificial pancreas," integrates CGM with automated insulin pumps to maintain optimal glycemic control. Such systems represent the vanguard of real-time, adaptive pharmacology [25].

21.5 Digital Pharmacovigilance

Pharmacovigilance, traditionally reliant on spontaneous reporting systems, is being fundamentally redefined by digital health and AI. Conventional systems, such as the FDA Adverse Event Reporting System (FAERS) or the WHO's VigiBase, depend on clinicians and patients voluntarily reporting suspected adverse drug reactions (ADRs). While valuable, these mechanisms often suffer from underreporting, reporting delays, and limited granularity. Digital pharmacovigilance harnesses real-world data from electronic health records, social media platforms, online patient forums, and wearable devices to provide near real-time surveillance of drug safety [26].

Natural language processing (NLP) has emerged as a powerful tool for extracting ADR-related signals from unstructured text such as clinical notes, social media posts, and online product reviews. For instance, Twitter and Reddit have been utilized to detect emerging safety concerns, such as adverse psychiatric effects of selective serotonin reuptake inhibitors, months before formal regulatory alerts [27]. Similarly, automated text-mining of EMRs can flag unusual symptom clusters that may indicate a previously unrecognized ADR.

Machine learning models enhance traditional disproportionality analysis by identifying subtle patterns in large datasets. Algorithms can integrate patient demographics, genomic profiles, and comorbidities to stratify ADR risk more precisely. During the COVID-19 vaccine rollout, digital pharmacovigilance systems monitored millions of online posts, helping to detect and contextualize rare adverse events such as myocarditis in younger populations [28].

Despite these advances, challenges remain. Digital platforms may generate a high rate of false positives due to misattribution of symptoms, incomplete information, or linguistic ambiguity. Additionally, ethical concerns arise around mining patient-generated data without explicit consent, and regulatory frameworks lag behind technological capabilities. Nevertheless, as digital pharmacovigilance matures, it promises to complement and eventually transform traditional systems, creating a more proactive, data-rich environment for drug safety monitoring [29].

21.6 AI in Clinical Trials

Clinical trials represent one of the most resource-intensive stages in drug development. Recruitment challenges, high costs, and logistical constraints have historically slowed trial progress and limited patient diversity. AI and digital health tools are revolutionizing clinical trials through innovations in recruitment, remote monitoring, and digital phenotyping. Virtual recruitment platforms

use AI-driven algorithms to screen electronic health records and patient registries for eligibility criteria, improving efficiency and inclusivity. For example, AI systems can rapidly identify oncology patients with specific biomarker profiles suitable for targeted therapy trials, reducing the time required to reach recruitment goals [30].

Decentralized trials, enabled by telemedicine, mobile apps, and wearable devices, allow participants to enroll and be monitored from their homes. This not only increases accessibility but also ensures greater representation of rural and underserved populations. Digital phenotyping — the use of data from smartphones, sensors, and digital interactions to infer health status — provides novel outcome measures beyond traditional biomarkers. For example, mobility data from smartphones can serve as surrogate markers for neurological disease progression [31].

AI also supports adaptive trial design by continuously analyzing interim data to modify protocols, optimize dosing regimens, or terminate unpromising arms earlier. This dynamic approach shortens development timelines and improves ethical trial conduct by reducing patient exposure to ineffective treatments [32]. However, AI-driven trials face hurdles such as data integration from heterogeneous sources, patient privacy concerns, and regulatory acceptance of novel digital endpoints. The future lies in hybrid models that combine traditional trial rigor with digital health flexibility, creating a more efficient, patient-centered paradigm for drug evaluation [33].

21.7 Ethical and Legal Challenges

The integration of AI and digital health in pharmacology raises profound ethical and legal challenges that must be addressed for sustainable implementation. Central among these is data privacy. Health data generated by wearables, mobile apps, and EMRs are highly sensitive, and breaches can undermine patient trust. While regulations such as HIPAA in the United States and GDPR in Europe provide frameworks for data protection, global harmonization is lacking, and enforcement remains uneven [34].

Algorithmic bias presents another major concern. AI systems trained on datasets that underrepresent certain populations may perpetuate health disparities by providing less accurate predictions for minority groups. This is particularly concerning in pharmacology, where dose-response relationships and ADR risks vary significantly across ethnicities and genotypes [35]. Informed consent becomes more complex in the context of AI-driven interventions. Patients may not fully understand how their data will be used, or how algorithmic decisions are generated. The opacity of “black-box” AI models further complicates accountability, raising questions about liability in cases of adverse outcomes [36].

Legal frameworks for telepharmacy and digital prescribing are still evolving. Issues such as cross-border licensure, malpractice liability in remote consultations, and the regulation of pharmacist chatbots highlight the need for updated laws that balance innovation with patient safety.

Ethical AI development requires transparency, explainability, and inclusive design practices that actively mitigate bias. Multi-stakeholder collaboration involving regulators, technologists, clinicians, and patient advocates will be essential to navigate these challenges. Ultimately, the success of digital pharmacology depends not only on technological innovation but also on ethical stewardship and legal clarity [37].

21.8 Telepharmacy and Virtual Services

Telepharmacy represents a natural extension of digital health into pharmaceutical services, bridging geographical and accessibility barriers. Defined as the provision of pharmacy services via

telecommunications, telepharmacy allows pharmacists to remotely counsel patients, monitor adherence, and manage complex therapies such as anticoagulation or oncology regimens [38].

During the COVID-19 pandemic, telepharmacy emerged as a critical modality for maintaining continuity of care. Remote counseling platforms enabled pharmacists to adjust medication regimens, detect potential drug–drug interactions, and provide medication education without requiring in-person visits. Studies have shown that telepharmacy interventions improve medication adherence and patient satisfaction, particularly in chronic diseases such as diabetes and hypertension [39].

Pharmacist chatbots, powered by NLP, are also being developed to provide 24/7 support for routine medication inquiries, such as side-effect management or missed doses. These virtual assistants augment but do not replace the clinical judgment of pharmacists, ensuring that human expertise remains central in complex cases.

The expansion of telepharmacy raises regulatory and reimbursement challenges. Licensure laws vary across jurisdictions, complicating cross-border service provision. Additionally, reimbursement frameworks often lag behind service delivery innovations, limiting scalability. Nevertheless, as healthcare systems increasingly embrace digital transformation, telepharmacy is poised to become an integral part of multidisciplinary care teams, ensuring equitable access to pharmaceutical expertise [40].



Figure 21.1: AI-Integrated Drug Discovery Workflow

Table 1: Comparative Overview of Traditional vs AI-Driven Drug Discovery

Aspect	Traditional Approach	AI-Driven Approach
Timeframe	10–15 years on average	Reduced by 30–50% through virtual screening
Cost	> USD 2 billion per new entity	Significant reduction due to in silico prioritization
Screening Method	High-throughput wet-lab screening	Virtual screening, ML-based compound generation
Attrition Rate	High (≤10% success)	Lowered through predictive modeling

Key Limitation	Expensive, labor-intensive	Algorithm transparency, need for wet-lab validation

Table 2: Applications of Digital Health Tools in Pharmacology

Technology	Pharmacological Application	Example Use Case
Mobile Health Apps	Medication adherence, dose tracking	Insulin dosing apps for diabetes
Wearables & Biosensors	PK/PD monitoring, biomarker detection	Continuous glucose monitoring
CDSS	Prescribing error reduction, dose adjustment	Antibiotic stewardship systems
Digital Pharmacovigilance	ADR signal detection	NLP analysis of social media
Telepharmacy	Remote medication counseling	Virtual pharmacist services in rural areas

21.9 Future Trends

The future of digital health and AI in pharmacology points toward increasingly immersive, predictive, and interconnected systems. The concept of the metaverse a virtual, interactive environment is being explored as a platform for patient education, therapy adherence, and even virtual clinical trials. Pharmacology training modules in the metaverse may allow healthcare providers to simulate drug interactions and patient scenarios in real time, enhancing experiential learning [41].

Digital twins represent another transformative innovation. These are virtual replicas of individual patients created by integrating genomic, proteomic, physiological, and lifestyle data. Digital twins can simulate drug responses in silico, allowing clinicians to test different therapeutic regimens before prescribing. This concept holds particular promise for complex polypharmacy scenarios, where interactions are difficult to predict experimentally [42].

Quantum computing is anticipated to accelerate molecular simulations far beyond current computational limits. By handling vast numbers of variables simultaneously, quantum systems could predict binding affinities, toxicity profiles, and metabolic pathways with unprecedented precision, further revolutionizing drug discovery [43]. Other emerging trends include the use of blockchain for secure health data sharing, the expansion of AI-enabled pharmacogenomics for precision dosing, and the integration of closed-loop systems that combine biosensors with automated drug delivery devices.

Ultimately, the convergence of these technologies will redefine pharmacology from a reactive science of drug response to a proactive discipline of drug anticipation and personalization. While challenges in ethics, equity, and regulation remain, the trajectory is clear: digital health and AI are ushering in an era of smarter, safer, and more patient-centered pharmacotherapy [44].

21.10 CONCLUSION

The integration of digital health and artificial intelligence into pharmacology represents one of the most significant paradigm shifts in modern medicine. From early-stage drug discovery to bedside decision support and post-marketing pharmacovigilance, digital innovations are reshaping the discipline into a more predictive, adaptive, and patient-centered science. AI-driven drug design and repurposing are shortening development timelines and reducing costs, while clinical decision-support systems and telepharmacy services are directly enhancing safety and accessibility in daily practice.

Mobile health applications, wearables, and biosensors empower patients to actively participate in their care, ensuring dynamic feedback loops between therapy and real-world outcomes.

At the same time, digital pharmacovigilance, AI-enabled clinical trials, and decentralized platforms are transforming regulatory science and real-world evidence generation. These advancements, however, are tempered by substantial ethical, legal, and operational challenges. Data privacy, algorithmic bias, interoperability, and informed consent remain persistent barriers that demand careful governance and international harmonization. Without addressing these concerns, the promise of digital pharmacology risks being undermined by inequities or mistrust.

Looking ahead, disruptive technologies such as digital twins, metaverse-based therapeutics, and quantum-enabled drug design will likely redefine the scope of pharmacological innovation. The ultimate goal is to transition from reactive pharmacotherapy toward a proactive, continuously optimized model of care tailored to individual patients. Success in this endeavor will depend not only on technical progress but also on collaborative stewardship across clinicians, technologists, regulators, and patients. By embedding ethics, transparency, and equity into innovation, digital health and AI can fulfill their potential to revolutionize pharmacology and ensure safer, smarter, and more inclusive therapeutic futures.

REFERENCES

1. Reddy S, Allan S, Coghlan S, Cooper P. A governance model for the application of AI in health care. J Am Med Inform Assoc. 2020;27(3):491-7.
2. Keesara S, Jonas A, Schulman K. Covid-19 and health care's digital revolution. N Engl J Med. 2020;382(23):e82.
3. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23(6):1241-50.
4. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56.
5. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-77.
6. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.
7. Zhavoronkov A, Ivanenkov YA, Aliper A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37(9):1038-40.
8. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83.
9. Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784-90.
10. Jiménez-Luna J, Grisoni F, Schneider G. Drug discovery with explainable AI. Nat Mach Intell. 2020;2(10):573-84.
11. Sutton RT, Pincock D, Baumgart DC, et al. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med. 2020;3:17.
12. Baysari MT, Westbrook JI. Safety of computerized physician order entry systems: a systematic review. Drug Saf. 2014;37(3):131-41.

13. Rawson TM, Moore LSP, Hernandez B, et al. A systematic review of clinical decision support systems for antimicrobial management: are we failing to investigate these interventions appropriately? Clin Infect Dis. 2020;71(3):655-62.
14. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24-9.
15. Khairat S, Coleman C, Ottmar P, et al. Physicians' experiences adopting clinical decision support systems: qualitative study. JMIR Med Inform. 2018;6(2):e10269.
16. Denny JC, Collins FS. Precision medicine in 2030 — seven ways to transform healthcare. Cell. 2021;184(6):1415-9.
17. Hou C, Xu Q, Diao S, Hewitt J, Li J, Carter B. Mobile phone applications and self-management of diabetes: a systematic review with meta-analysis, meta-regression of 21 randomized trials. JMIR Mhealth Uhealth. 2018;6(12):e12297.
18. Desteghe L, Hendriks J, McEvoy RD, et al. Mobile health applications for atrial fibrillation management: a systematic review and meta-analysis. Eur Heart J. 2018;39(16):1401-14.
19. Omboni S, McManus RJ, Bosworth HB, et al. Evidence and recommendations on the use of telemedicine for the management of arterial hypertension. Hypertension. 2020;76(5):1368-83.
20. Byambasuren O, Beller E, Glasziou P. Current knowledge and adoption of mobile health apps among Australian general practitioners: survey study. JMIR Mhealth Uhealth. 2019;7(6):e13199.
21. Jeong IC, Bychkov D, Searson PC. Wearable devices for precision medicine and health state monitoring. IEEE Trans Biomed Eng. 2019;66(5):1242-58.
22. Heikenfeld J, Jajack A, Rogers J, et al. Wearable sensors: modalities, challenges, and prospects. Lab Chip. 2018;18(2):217-48.
23. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127(1):95.e11-7.
24. Dunn J, Runge R, Snyder M. Wearables and the medical revolution. Per Med. 2018;15(5):429-48.
25. Boughton CK, Hovorka R. Is an artificial pancreas (closed-loop system) for type 1 diabetes realistic? Diabetologia. 2019;62(5):743-51.
26. Bate A, Evans SJ. Pharmacovigilance using big data: the power of digital evidence. Clin Pharmacol Ther. 2009;86(5):477-9.
27. Sarker A, Ginn R, Nikfarjam A, et al. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015;54:202-12.
28. Al-Gumaei M, Alzoubi KH, Abushamma F, et al. Digital pharmacovigilance in the era of COVID-19 vaccines. Vaccine. 2022;40(34):4981-90.
29. Trifirò G, Mokraoui NM, Al-Balushi KA, et al. The role of big data in the future of pharmacovigilance. Int J Clin Pharm. 2018;40(5):1223-31.
30. Krittanawong C, Johnson KW, Rosenson RS, et al. Deep learning for cardiovascular medicine: a practical primer. Eur Heart J. 2019;40(25):2058-73.
31. Onnela JP, Rauch SL. Harnessing smartphone-based digital phenotyping to enhance behavioral and mental health. Neuropsychopharmacology. 2016;41(7):1691-6.
32. Alexander BM, Baumann BC, Burris HA, et al. Enhancing clinical trial efficiency through the use of historical control data. J Clin Oncol. 2020;38(7):735-9.
33. Izmailova ES, Ellis R, Benko C. Remote monitoring in clinical trials during the COVID-19 pandemic. Clin Transl Sci. 2020;13(5):838-41.

34. Mittelstadt BD, Floridi L. The ethics of big data: current and foreseeable issues in biomedical contexts. Sci Eng Ethics. 2016;22(2):303-41.
35. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53.
36. Morley J, Machado CCV, Burr C, et al. The ethics of AI in health care: a mapping review. PLoS One. 2020;15(9):e0239947.
37. Leslie D. Understanding artificial intelligence ethics and safety. London: The Alan Turing Institute; 2019.
38. Baldoni S, Amenta F, Ricci G. Telepharmacy services: present status and future perspectives: a review. Medicina (Kaunas). 2019;55(7):327.
39. Poudel A, Nissen LM. Telepharmacy: a pharmacist's perspective on the clinical benefits and challenges. Integr Pharm Res Pract. 2016;5:75-82.
40. Stratton TP. Telepharmacy: a new paradigm for our profession. J Pharm Technol. 2015;31(5):181-4.
41. Spanakis EG, Santana S, Tsiknakis M, et al. Technology-based innovations to foster personalized healthy lifestyles and wellbeing: a targeted review. NPJ Digit Med. 2022;5(1):84.
42. Björnsson B, Borrebaeck C, Elander N, et al. Digital twins to personalize medicine. Genome Med. 2020;12(1):4.
43. Cao Y, Romero J, Olson JP, Aspuru-Guzik A. Potential of quantum computing for drug discovery. IBM J Res Dev. 2018;62(6):6:1-20.
44. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. Wiley Interdiscip Rev Data Min Knowl Discov. 2019;9(4):e1312.